Corcept Therapeutics (CORT)
(Real Time Quote from BATS)
$70.84 USD
-0.93 (-1.30%)
Updated Aug 5, 2025 03:08 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CORT 70.84 -0.93(-1.30%)
Will CORT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar?
Other News for CORT
CORT: Today's Analyst Rating Update and Price Target Adjustment | CORT Stock News
Corcept Therapeutics (CORT) Target Price Revised by Piper Sandler Analyst
Corcept Therapeutics (CORT) Price Target Lowered, Buy Rating Maintained
ClearBridge Small Cap Fund Q2 2025 Commentary
Piper Sandler Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News